Cancer Research UK and ORIC partner on CIP2A-targeted therapy
Cancer Research UK has signed an agreement with ORIC Pharmaceuticals to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.
Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase I/II clinical trial of ORIC-259, including CTA-enabling studies, for patients with cancer.
ORIC retains an option to reacquire rights to ORIC-259 following Phase I/II data, with Cancer Research UK eligible to receive downstream milestone payments and royalties.
ORIC-259 is a splice-modifier directed against CIP2A, a cancer-driving protein that has traditionally been considered undruggable.
CIP2A plays multiple roles in cancer progression and is associated with tumour growth and survival across numerous cancer types, making it an attractive target for the development of potential new cancer treatments.
The Phase I/II trial will assess the safety, tolerability and preliminary anti-tumour activity of the molecule, generating important data to determine whether targeting CIP2A could offer a new therapeutic approach across a range of tumour types.
Overcoming treatment resistance in cancer
A potential area of application is in BRCA-mutant cancers, where research has identified CIP2A as a synthetic lethal vulnerability. Because CIP2A targeting has a distinct mechanism from PARP, ORIC-259 could offer a new approach for patients whose cancers have become resistant to PARP inhibitors, while also creating opportunities to combine CIP2A-targeted therapies with PARP inhibitors or other agents.
Lars Erwig, Director of the CDD, said: “ORIC-259 represents an innovative approach to targeting CIP2A, a protein with significant potential in cancer but one that has proven difficult to drug. We share ORIC’s mission to overcome treatment resistance in cancer, and we look forward to applying our expertise to explore new treatment options for patients.”
Lori Friedman, Chief Scientific Officer of ORIC, added: “Cancer Research UK’s proven expertise and capabilities in developing innovative cancer therapies make it an ideal partner for the programme, while this structure allows us to remain disciplined in allocating our internal resources to our late-stage clinical pipeline.”
